Dr. Palevsky is Co-Chair of VA PRESERVE study (Prevention of Serious Adverse Events Following Angiography), a multicenter randomized controlled trial that enrolled nearly 5,200 patients to evaluate strategies for the prevention of adverse renal outcomes following radiocontrast administration being conducted at 33 VA study sites in the United States as well as at international sites. A biorepository for analysis of potential biomarkers of kidney injury in nearly 1,000 patients has been created with funding from the NIDDK. Dr. Palevsky is also leading a US consortium that hopes to participate in the multinational Standard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial. Dr. Palevsky is participating in the PreCISE AKI study, which will be obtaining kidney biopsies from patients with early acute kidney injury as part of the NIDDKs Kidney Precision Medicine Project (KPMP) consortium. Other areas of research include progression of CKD, management of symptoms in patients with CKD and ESRD and implementation of quality improvement in CKD and ESRD.